Neuroprotective Potentials of Ageratum conyzoides Phyto-constituents via Inhibition of Monoamine Oxidase: An In-silico Study
Abstract
A surge of monoamine oxidase (MAO) causes neurodegenerative disorders like depression linked to suicides among youths. The goal of this work was to use a molecular docking technique to predict the neuroprotective potentials of phytoconstituents found in Ageratum conyzoides leaves (ACL), a popular folk remedy for neurological disorders. The 23 phytoconstituents previously found in ethanol leaf extract of ACL (ACL1-23) were identified and their 3D structures were either sketched (ACD/ChemSketch) or downloaded from the PubChem website. MAO was the target protein, and phenelzine (PNZ) was the standard inhibitor. The protein structure was obtained from the Protein Data Bank and processed for docking with UCSF Chimera. Before molecular docking with the AutoDock Vina Plugin PyRx, the 23 ACL bioactive compounds were tested for blood-brain barrier (BBB) permeability and other pharmacological characteristics. The protein-ligand interactions were visualized using the Discovery Studio 2020 after docking. The result revealed that all other ACL bioactive compounds were shown to potentially be BBB-permeants with good pharmacological characteristics, except for ACL17 and ACL18 bioactive compounds. Standard inhibitor indicated two binding pockets within the protein, and all BBB-permeants bound to any of the two pockets. The PNZ had docking values of -6.8 and -6.0 kcal/mol at the pockets; whereas the ACL had docking values ranging from -6.7 to -4.6 kcal/mol. ACL similarly interacted with MAO as the PNZ, indicating that they are competitive inhibitors and therapeutics. We reported a step forward in the discovery of greener neuroprotective drugs and their molecular mechanisms to combat neurodegenerative illnesses.
Downloads
References
Aarre, T. F. (2003). Phenelzine efficacy in refractory social anxiety disorder: a case series. Nord Journal of Psychiatry, 57(4), 313–315.
Aja, P. M., Agu, P. C., Ezeh, E. M., Awoke, J. N., Ogwoni, H. A., TusubiraDeusdedit, Ekpono, E. U., Igwenyi, I. O., Alum, E. U., Ugwuja, E. I., Ibiam, A. U., Afiukwa, C. A. and Abayomi E. A. (2021). Prospect into therapeutic potentials of Moringa oleifera phytocompounds against cancer upsurge: de novo synthesis of test compounds, molecular docking, and ADMET studies. Bulletin of National Research Centre, 45(1), 99.
Aja, P. M., Enechi, O. C., Ozougwu, V. E. O., Onya-Mmaghiri, E. A., Agu, K. A., Ali Ikechukwu, A. and Nweke, O. L. (2016). Phytochemical composition, gas chromatography-mass spectrometric (GC-MS) analysis and anti-bacterial activity of ethanol leaf-extract of Ageratum conyzoides. African Journal of Basic and Applied Sciences, 8(1), 34-40.
Al-Nuaimi, S. K., MacKenzie, E. M. and Baker, G. B. (2012). Monoamine oxidase inhibitors and neuroprotection: a review. American Journal of Therapy, 19(6), 436–448.
Aluf, Y., Vaya, J., Khatib, S., Loboda, Y. and Finberg, J. P. (2013). Selective inhibition of monoamine oxidase A or B reduces striatal oxidative stress in rats with partial depletion of the nigro-striatal dopaminergic pathway. Neuropharmacology, 65, 48–57.
Ansari, M. A., Abdul, H. M., Joshi, G., Opii, W. O. and Butterfield, D. A. (2009). Protective effect of quercetin in primary neurons against Aβ (1–42): relevance to Alzheimer’s disease. Journal of Nutritional Biochemistry, 20(4), 269– 75.
Bak, T. H., & Chandran, S. (2012). What wires together dies together: verbs, actions and neurodegeneration in motor neuron disease. Cortex, 48(7), 936-944.
Baker, G. B., Matveychuk, D., MacKenzie, E. M., Dursun, S. M., &Mousseau, D. D. (2012). Monoamine oxidase inhibitors and neuroprotective mechanisms. KlinikPsikofarmakolojiBülteni-Bulletin of Clinical Psychopharmacology, 22(4), 293-296.
Blier, P. (2016). Neurobiology of depression and mechanism of action of depression treatments. The Journal of Clinical Psychiatry, 77(3), 26392.
Brue, A. W. and Oakland, T. D. (2002). Alternative treatments for attention deficit hyperactivity disorders: Does evidence support their use? Alternative Therapy in Medicine, 8(1), 68-74.
Cagle, B. S., Crawford, R. A., &Doorn, J. A. (2019). Biogenic aldehyde-mediated mechanisms of toxicity in neurodegenerative disease. Current Opinion in Toxicology, 13, 16-21.
Cai, Z. (2014). Monoamine oxidase inhibitors: promising therapeutic agents for Alzheimer’s disease (Review). Molecular Medicine of Reproduction,9(5), 1533– 1541.
Chen, A. T. and Nasrallah, H. A. (2019). Neuroprotective effects of the second-generation antipsychotics. Schizophrenia Research, 208, 1–7.
Doble, A. (1999). The role of excitotoxicity in neurodegenerative disease: implications for therapy. Pharmacology of Therapy, 81(3), 163–221.
Drevets, W. C., Frank, E., Price, J. C., Kupfer, D. J., Holt, D., Greer, P. J., Huang, Y., Gautier, C. and Mathis, C. (1999). PET imaging of serotonin 1A receptor binding in depression. Biology and Psychiatry, 46(10), 1375-87.
Finberg, J. P. M. and Rabey, J. M. (2016). Inhibitors of MAO-A and MAO-B in psychiatry and neurology. Frontier in Pharmacology, 7, 340
Finkbeiner, S. (2011). Huntington’s disease. Cold Spring Harb Prospects in Biology, 3(6), 1–24.
Fowler, J. S., Logan, J., Volkow, N. D., Wang, G. J., MacGregor, R. R. and Ding, Y. S. (2002). Monoamine oxidase: radiotracer development and human studies. Methods,27(3), 263–277.
Hartman, R. E., Shah, A. and Fagan, A. M. (2006). Pomegranate juice decreases amyloid load and improves behavior in a mouse model of Alzheimer’s disease. Neurobiology Diseases, 24(3), 506–15.
Hill, R. L., Singh, I. N., Wang, J. A., Kulbe, J. R., & Hall, E. D. (2020). Protective effects of phenelzine administration on synaptic and non-synaptic cortical mitochondrial function and lipid peroxidation-mediated oxidative damage following TBI in young adult male rats. Experimental neurology, 330, 113322.
Holmes, C. and Amin, J. (2016). Dementia. Medicine (Baltimore), 44: 687–90.
Hunsberger, J., Austin, D. R., Henter, I. D. and Chen, G. (2009). The neurotrophic and neuroprotective effects of psychotropic agents. Dialogues of Clinical Neuroscience, 11, 333–348.
Jasvidianto C. K., Agatha B. S. L., Damiana S. C. and Maywan H. (2020). Medicinal effect, in silico bioactivity prediction, and pharmaceutical formulation of Ageratum conyzoides L.: A Review. Scientifica, 2020:12.
Jhamandas, J. H., Wie, M. B., Harris, K., MacTavish, D. and Kar, S. (2005). Fucoidan inhibits cellular and neurotoxic effects of β-amyloid (Aβ) in rat cholinergic basal forebrain neurons. European Journal of Neuroscience, 21(10), 2649–59.
Jossan, S. S., Hiraga, Y., & Oreland, L. (1989). The cholinergic neurotoxin ethylcholine mustard aziridinium (AF64A) induces an increase in MAO-B activity in the rat brain. Brain Research, 476(2), 291-297.
Jossan, S., Gillberg, P., Gottfries, C., Karlsson, I. and Oreland, L. (1991). Monoamine oxidase B in brains from patients with Alzheimer’s disease: a biochemical and autoradiographical study. Neuroscience, 45: 1–12.
Kalia, L. V., & Lang, A. E. (2015). Parkinson's disease. The Lancet, 386(9996), 896-912.
Kolominsky-Rabas, P. L., Sarti, C., Heuschmann, P. U., Graf, C., Siemonsen, S., Neundoerfer, B., et al. (1998). A prospective community-based study of stroke in Germany. The erlangen stroke project (ESPro): Incidence and case fatality at 1, 3, and 12 months. Stroke, 29(12), 2501-6.
Li, X. M. and Xu, H. (2007) Evidence for neuroprotective effects of antipsychotic drugs: implications for the pathophysiology and treatment of schizophrenia. International Review on Neurobiology,77, 107–142.
Lieberman, J. A., Bymaster, F. P., Meltzer, H. Y et al. (2008). Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection. Pharmacological Review, 60(3), 358–403.
Manzoor, S. and Hoda, N. (2020). A comprehensive review of monoamine oxidase inhibitors as Anti-Alzheimer’s disease agents: a review. European Journal of Medicinal Chemistry, 206, 112787.
Masato, A., Plotegher, N., Boassa, D., &Bubacco, L. (2019). Impaired dopamine metabolism in Parkinson’s disease pathogenesis. Molecular Neurodegeneration, 14(1), 1-21.
Matveychuk, D., MacKenzie, E. M., Kumpula, D., Song, M-S., Holt., A., Kar, S., · Todd, K. G., Wood, P. L. and Baker, G. B. (2022). Overview of the Neuroprotective Efects of the MAO Inhibiting Antidepressant Phenelzine. Cellular and Molecular Neurobiology, 42, 225–242.
Nam, D. T., Arseneault, M., Murthy, V. and Ramassamy, C. (2010). Potential role of acrolein in neurodegeneration and Alzheimer’s disease. Current Molecular Pharmacology, 3(3), 66–78.
Ortiz, J. G., Nieves-Natal, J. and Chaves, P. (1999). Effects of Valerianaofficinalis extracts on [3H] flunitrazepam binding, synaptosomal [3H] GABA uptake, and hippocampal [3H] GABA release. Neurochemistry Research, 24(11), 1373-8.
Panneton, W. M., Kumar, V. B., Gan, Q., Burke, W. J., & Galvin, J. E. (2010). The neurotoxicity of DOPAL: behavioral and stereological evidence for its role in Parkinson disease pathogenesis. PLoS One, 5(12), e15251.
Pathak, N. L., Sanjay, B. K., Bhatt, N. M. and Patel, R. G. (2011). Experimental Modeling of Anxiety. Journal of Applied Pharmaceutical Science, 01(03), 06-10.
Phani-Kumar, G. and Khanum, F. (2012). Neuroprotective potential of phytochemicals. Pharmacognosy Reviews, 6(12), 81.
PhaniKumar, G., Anilakumar, K.R. and Naveen, S. (2015). Phytochemicals Having Neuroprotective Properties from Dietary Sources and Medicinal Herbs. Pharmacognosy Journal, 7(1), 1-5.
Practico, D. (2008). Oxidative stress hypothesis in Alzheimer’s disease: a reappraisal. Trends in Pharmacological Science, 29(12), 609–615.
Quartey, M. O., Nyarko, J. N. K., Pennington, P. R., Heistad, R. M., Klassen, P. C., Baker, G. B. and Mousseau, D. D. (2018). Alzheimer's disease and selected risk factors disrupt a co-regulation of monoamine oxidase-A/B in the hippocampus, but not in the cortex. Frontier Neuroscience,12, 419.
Raheela, J., Muhammad, S., Amer, J and Muhammad, A (2008). Composition of Cajanuscajan Leaf and Seed. Pakistan Journal of Botany, 40(4), 1349-1358.
Riederer, P., Danielczyk, W., &Grünblatt, E. (2004). Monoamine oxidase-B inhibition in Alzheimer’s disease. Neurotoxicology, 25(1-2), 271-277.
Shanahan, P., O’Sullivan, J., Tipton, K. F., Kinsella, G. K., Ryan, B. J. and Henehan, G. T. M. (2019). Theobromine and related methylxanthines as inhibitors of Primary Amine Oxidase. Journal of Food Biochemistry, 43(2), e12697.
Shemyakov, S. E. (2001). Monoamine oxidase activity, lipid peroxidation, and morphological changes in human hypothalamus during aging. Bulletin of Experimental Biology and Medicine, 131, 586-588.
Sherif, F., Gottfries, C. G., Alafuzof, I. and Oreland, L. (1992). Brain gamma-amino butyrate aminotransferase (GABA-T) and monoamine oxidase (MAO) in patients with Alzheimer’s disease. Journal of Neural Transmission in Parkinson Disease and Dementia Sections, 4, 227–240.
Song, M. S., Matveychuk, D., MacKenzie, E. M., Duchcherer, M., Mousseau, D. D. and Baker, G. B. (2013). An update on amine oxidase inhibitors: multifaceted drugs. Prog Neuropsychopharmacology, Biology, and Psychiatry,44, 118–124.
Szökő, É., Tábi, T., Riederer, P., Vécsei, L. and Magyar, K. (2018). Pharmacological aspects of the neuroprotective effects of irreversible MAO-B inhibitors, selegiline, and rasagiline, in Parkinson’s disease. Journal of Neural Transmission, 125, 1735–1749.
Tatton, W., Chalmers-Redman, R. and Tatton, N. (2003). Neuroprotection by deprenyl and other propargylamines: glyceraldehyde3-phosphate dehydrogenase rather than monoamine oxidase B. Journal of Neural Transmission,110(5), 509–515.
Van-Burden, L. and Robinsin, J. H. (1981). Phytochemical Techniques of plant analysis,2nd edition, New York, pp: 100-150.
Volchegorskii, I. A., Shemyakov, S. E., Turygin, V. V. and Malinovskaya, N. V. (2001). Comparative analysis of age-related changes in activities of monoamine oxidase-B and antioxidant defense enzymes in various structures of human brain. Bulletin of Experimental Biology and Medicine,132, 760–762.
Wang, W., Gao, C., Hou, X. Y., Liu, Y., Zong, Y. Y., & Zhang, G. Y. (2004). Activation and involvement of JNK1/2 in hydrogen peroxide-induced neurotoxicity in cultured rat cortical neurons. Acta Pharmacologica Sinica, 25(5), 630-636.
Wood, P., Khan, M. and Moskal, J. (2007). The concept of “aldehyde load” in neurodegenerative mechanisms: cytotoxicity of the polyamine degradation products hydrogen peroxide, acrolein, 3-aminopropanal, 3-acetamidopropanal and 4-aminobutanal in a retinal ganglion cell line. Brain Research,1145, 150–156.
Yang, L., Omori, K., Suzukawa, J., & Inagaki, C. (2004). Calcineurin-mediated BAD Ser155 dephosphorylation in ammonia-induced apoptosis of cultured rat hippocampal neurons. Neuroscience Letters, 357(1), 73-75.
Yang, L., Omori, K., Omori, K., Otani, H., Suzukawa, J., & Inagaki, C. (2003). GABAC receptor agonist suppressed ammonia‐induced apoptosis in cultured rat hippocampal neurons by restoring phosphorylated BAD level. Journal of Neurochemistry, 87(3), 791-800.
Yehuda, S., Rabinovitz, S. and Carasso, R. L. (2002). The role of polyunsaturated fatty acids in restoring the aging neuronal membrane. Neurobiology and Aging, 23(5), 843-53.
Zhang, W. and Davidson, J. R. (2007). Post-traumatic stress disorder: an evaluation of existing pharmacotherapies and new strategies. Expert Opinion Pharmacotherapy, 8(12), 1861–1870.
Additional Files
Published
Issue
Section
Categories
License
Copyright (c) 2023 Peter Chinedu Agu, Dr. Aja, Dr. Ezeh, Dr. Ekpono
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
